Bruton's tyrosine kinase

Receptor

Expanded Disability Status Scale

Placebo

Immunology

Alternative medicine

Tyrosine kinase

Internal medicine

Clinical endpoint

Multiple sclerosis

Medicine

Gastroenterology

Randomized controlled trial

Pathology

New England Journal of Medicine

Bruton’s tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis